To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP)...
Date First Received: January 1, 2008
Last Updated: October 6, 2008
Verified by: Pfizer, October 2008
Clinical Trial Phase: Phase 3 | Start Date: September 2006
Overall Status: Recruiting
Estimated Enrollment: 200
Brief Summary
Official Title: “A Phase III Placebo-Controlled Trial Of Celecoxib In Genotype Positive Subjects With Familial Adenomatous Polyposis”
Condition Keyword(s):
Intervention(s):
To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP).
Study Type: Interventional
Study Design: Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study
Study Primary Completion Date: May 2017
Intervention(s) in this Clinical Trial
- Drug: Celecoxib
- celecoxib, 16 mg/kg/day, for 5 years
- Drug: Placebo
- Masked, placebo comparator
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: Celecoxib
- celecoxib, 16 mg/kg/day, for 5 years
- Placebo Comparator: Placebo
- Masked, placebo comparator
Outcome Measures for this Clinical Trial
Primary Measures
- To compare the time from randomization to treatment failure over a 5 year period in subjects treated with celecoxib vs placebo.
- Time Frame: 5 years
Safety Issue?: No
- Time Frame: 5 years
Secondary Measures
- To compare colorectal polyp burden over 5 years for subjects treated with celecoxib versus subjects treated with placebo.
- Time Frame: 5 years
Safety Issue?: No
- Time Frame: 5 years
- To compare in the intent-to-treat population the time from randomization to treatment failure for subjects treated with celecoxib versus subjects treated with placebo
- Time Frame: 5 years
Safety Issue?: No
- Time Frame: 5 years
- To compare between subjects treated with celecoxib versus subjects treated with placebo the total number of colorectal polyps (>2 mm in size) detected over years 1-5 cumulatively.
- Time Frame: 5 years
Safety Issue?: No
- Time Frame: 5 years
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Age 10-17 years
- Confirmed non-attenuated FAP genotype based on central genetic testing
- Less than 20 polyps, which need to be removed to render the colon polyp-free before study drug can be given
Exclusion Criteria:
- Diagnosis of attenuated FAP based on central genetic testing
- Sensitivity to COX-2 inhibitors
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 10 Years
Maximum Age for this Clinical Trial: 17 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Pfizer
Overall Clinical Trial Officials and Contacts
Pfizer CT.gov Call Center Study Director Pfizer
Overall Contact: Pfizer CT.gov Call Center 1-800-718-1021
Additional Information
Information obtained from ClinicalTrials.gov on October 10, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00585312
Study ID Number: A3191193
ClinicalTrials.gov Identifier: NCT00585312
Health Authority: United States: Food and Drug Administration
To obtain contact information for a study center near you, click here.
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.